Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Pomalidomide Celgene

- PMLiVE

Celgene’s Revlimid scores NICE approval in follicular lymphoma

New ‘chemotherapy-free’ treatment for patients with limited options

- PMLiVE

FDA begins speedy review of BMS’ CAR-T liso-cel

Agency sets target action date of 17 August for final decision

- PMLiVE

Janssen files new Darzalex combination for multiple myeloma

Expands use of anti-CD38 antibody even further

- PMLiVE

UPDATED: J&J expands US partnership for coronavirus treatments

Expands on exisiting alliance announced last week

- PMLiVE

Celgene drugs drive BMS to a buoyant Q4, but Opdivo stalls

BMS share price up by 3% on the back of results

- PMLiVE

GSK and Gilead join global efforts to tackle novel coronavirus

Confirmed cases rise to over 17,000 in China

- PMLiVE

J&J begins search for a coronavirus vaccine as confirmed cases rise

Death toll has now reached 170, with 7,711 confirmed cases in China

- PMLiVE

J&J gets EMA nod for wider use of Erleada in prostate cancer

Maintains a regulatory lead over rival Xtandi

- PMLiVE

NICE knocks back J&J’s depression nasal spray Spravato

Cites clinical and pricing uncertainty as basis of rejection

- PMLiVE

FDA fast-tracks GSK’s anti-BCMA drug for multiple myeloma

If approved will become first BCMA targeting drug for myeloma

- PMLiVE

J&J wins another label expansion for Darzalex in Europe

Multiple myeloma treatment indicated for early use

- PMLiVE

J&J pushes to expand Imbruvica label after clinical success

Eyes the frontline setting in chronic lymphocytic leukaemia

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links